A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC

被引：3

作者：

Goldberg, S. B. ^{[1
]}

Balmanoukian, A. ^{[2
]}

Chaft, J. ^{[3
]}

Rizvi, N. ^{[4
]}

Sanborn, R. E. ^{[5
]}

Rebelatto, M. C. ^{[6
]}

Narwal, R. ^{[7
]}

Robbins, P. B. ^{[6
]}

Gu, Y. ^{[8
]}

Karakunnel, J. J. ^{[9
]}

Antonia, S. ^{[10
]}

机构：

[1] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[2] Angeles Clin & Res Inst, Dept Hematol Oncol, Los Angeles, CA USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[4] Columbia Univ Hosp, Dept Med, New York, NY USA

[5] Earle A Chiles Res Inst, Providence Canc Ctr, Thorac Oncol, Portland, OR USA

[6] Medimmune Inc, Translat Med, Gaithersburg, MD 20878 USA

[7] Medimmune Inc, Clin Pharmacol & DMPK, Gaithersburg, MD 20878 USA

[8] Medimmune Inc, Biostat, Gaithersburg, MD 20878 USA

[9] Medimmune Inc, Clin Dev, Gaithersburg, MD 20878 USA

[10] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

来源：

关键词：

D O I：

10.1016/S0959-8049(16)31727-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3086

引用

页码：S627 / S627

页数：1